CompletedPhase 3

Follow-up Efficacy and Safety of Alitretinoin in Severe Chronic Hand Dermatitis

Germany300 participantsStarted 2005-03

Plain-language summary

Patients who have been treated in study protocol BAP089 may have responded to treatment, and subsequently relapsed to \>75% of the baseline disease severity, will be investigated for response to further treatment with alitretinoin. Also, patients who have responded with mild or moderate disease will be investigated for additional treatment effect after prolongated treatment.

Who can participate

Age range18 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Previous participation in protocol BAP089 * Response of severe, treatment refractory hand dermatitis with mild or moderate, or responding patients who relapsed to 75% of baseline disease Exclusion Criteria: * Female patients who are pregnant or who want to become pregnant * Female patients of child bearing potential who cannot use or who will not commit to using two effective methods of contraception

What they're measuring

Response of chronic hand dermatitis to study treatment as assessed by Physicians Global Assessment, at week 12 or 24

Trial details

NCT IDNCT00124436

SponsorBasilea Pharmaceutica

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2007-01

View on ClinicalTrials.gov More Hand Dermatoses trials